
光動力治療創新實驗室
Photodynamic Innovative Laboratory
Publications

2023
-
Wei-Ting Liu, Han-Tang Wang, Yi-Hsuan Yeh, and Tak-Wah Wong.* An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas. Pharmaceutics. Accepted April 22,2023. Impact factor 6.525, Journal Rank: JCR - Q1 (Pharmacology & Pharmacy)
Figure. Photodynamic therapy as an adjunctive treatment in primary cutaneous lymphomas in 2 patients. A 63-year-old woman with stage IIA mycosis fungoides who received oral retinoid acid and UVB phototherapy except for the face due to the fear of skin darkening. (a) There are a few well-demarcated scaly erythematous patches on the forehead that responded poorly to topical treatments. (b) 5-aminolevulinic acid (ALA)-PDT consisted of 50 J/cm2 visible light (MediLED PDT, Mediland, Taoyuan City, Taiwan) irradiance after occlusion of 5-aminolevulinic acid (Ameluz, Biofrontera AG, Leverkusen, Germany) for 3 h given every other week for 3 sessions, and strong fluorescence was shown under Wood’s light examination. (c) After 3 treatment sessions, the erythematous scaly patches over the forehead improved greatly, although a histological exam over the right forehead lesion revealed residual atypical lymphocytes. (d) A 56-year-old woman with mycosis fungoides and lymphomatoid papulosis developed new crops of papules over the V-chest despite being under treatments with twice-weekly PUVA phototherapy and weekly 10 mg oral methotrexate. (e) Vivid coral-red fluorescence was detected under Wood’s lamp illumination after occlusion with ALA for 3 h. (f) Significant improvement was achieved after a single treatment with 100 J/cm2 visible light irradiation at 2-week follow-up.


